FIGURE 2.

Proportion of patients requiring oral corticosteroid (OCS) maintenance therapy and daily median prednisone‐equivalent dose in the on‐treatment analysis (A, B) and the on/off‐treatment analysis (C, D). For both on‐treatment and on/off‐treatment analyses, follow‐up was ended at the first instance of any of the following: 1‐year post‐mepolizumab initiation, claim for another asthma biologic, or 3 days prior to first bronchial thermoplasty; for the on‐treatment analysis, follow‐up was also ended upon mepolizumab discontinuation (>90 days without another mepolizumab injection); In (B) and (D), the error bars indicate the interquartile range and the n numbers at the bottom of the bars indicate the number of patients. ^†Baseline OCS maintenance was defined as a mean daily dose ≥5 mg/day OCS with <15‐day gap for the 3‐month before index; ^‡Median percentage reduction from baseline; median of pairwise comparisons: results may differ from calculations made on summary values shown above the bars. OCS, oral corticosteroids; Q, quarter